NLS Pharmaceutics (NLSP) Institutional Ownership $1.46 +0.03 (+2.10%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$1.44 -0.02 (-1.64%) As of 04/17/2025 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for NLS Pharmaceutics (NASDAQ:NLSP)Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$30.15KNumber ofInstitutional Sellers(last 12 months)0 Get NLSP Insider Trade Alerts Want to know when executives and insiders are buying or selling NLS Pharmaceutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data NLSP Institutional Buying and Selling by Quarter NLS Pharmaceutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/15/2024Armistice Capital LLC2,311,000$501K0.0%+6.4%19.618% 11/15/2023Affinity Asset Advisors LLC200,455$140K0.0%-49.9%0.000% 8/21/2023Affinity Asset Advisors LLC400,000$440K0.2%+16.2%0.000% 5/15/2023Affinity Asset Advisors LLC344,089$520K0.2%N/A2.921% 11/16/2021Two Sigma Securities LLC10,140$25K0.0%N/A0.086% 8/13/2021Renaissance Technologies LLC41,997$132K0.0%N/A0.357% 5/20/2021Axiom Investment Management LLC68,000$273K0.1%N/A0.577% 5/18/2021Millennium Management LLC33,213$134K0.0%N/A0.282% (Data available from 1/1/2016 forward) NLSP Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of NLSP shares? During the previous two years, the following institutional investors and hedge funds held shares of NLS Pharmaceutics shares: Armistice Capital LLC ($501K), Affinity Asset Advisors LLC ($140K).Learn more on NLSP's institutional investors. Which institutional investors have been buying NLS Pharmaceutics stock? The following institutional investors have purchased NLS Pharmaceutics stock in the last 24 months: Affinity Asset Advisors LLC ($400K), and Armistice Capital LLC ($139K). How much institutional buying is happening at NLS Pharmaceutics? Institutional investors have bought a total of 539,000 shares in the last 24 months. This purchase volume represents approximately $614.67K in transactions. Which NLS Pharmaceutics major shareholders have been selling company stock? The following institutional investors have sold NLS Pharmaceutics stock in the last 24 months: Affinity Asset Advisors LLC ($199.55K). How much institutional selling is happening at NLS Pharmaceutics? Institutional investors have sold a total of 199,545 shares in the last 24 months. This volume of shares sold represents approximately $139.68K in transactions. Related Companies CEL-SCI Major Shareholders Enlivex Therapeutics Major Shareholders Natural Alternatives International Major Shareholders ProMIS Neurosciences Major Shareholders NanoViricides Major Shareholders Mural Oncology Major Shareholders BioAtla Major Shareholders Annovis Bio Major Shareholders Elevation Oncology Major Shareholders Equillium Major Shareholders This page (NASDAQ:NLSP) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | Sponsored100-year-old investment secret predicts what?!A 100-year-old indicator has quietly predicted nearly every major market meltdown — including the Dot-Com Bust...Weiss Ratings | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | Sponsored2025 could be "worse than the dot-com bust", says man who predicted 2008 banking crisisWhat's coming next to the U.S. market could be worse than anything we've ever seen before – worse than the dot...Stansberry Research | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NLS Pharmaceutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NLS Pharmaceutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
